Sandoz’s Filgrastim Biosimilar Relies On Data Extrapolation
This article was originally published in The Pink Sheet Daily
Executive Summary
351(k) application seeks approval for full array of indications carried by Amgen’s Neupogen, which could give Sandoz product a competitive advantage over Teva’s marketed tbo-filgrastim, approved as traditional BLA.
You may also be interested in...
Celltrion’s Remicade Biosimilar Takes U.S. Regulatory Shortcuts
After just one year of working with the U.S FDA, the South Korean company is positioning itself to launch its first monoclonal antibody biosimilar in the U.S. market.
Teva’s G-CSF Product Clears FDA, Leaving Appeal Of Biosimilar Pathway Uncertain
Teva is the first company to get FDA approval of a version of Amgen’s Neupogen; one biosimilar expert questions why Teva did not switch its BLA to a biosimilar application when that pathway became available.
FDA Biosimilars Guidances Address Immunogenicity Studies, European Bridge Data, Analytics
The agency’s first three draft guidances on biosimilar product development describe how to characterize biosimilar and reference products and extrapolate data on one condition of use to another. FDA says interchangeability is difficult to determine now and will require a switching study.